Not GMO: A new way to get CRISPR/Cas9 into plant cells without inserting foreign DNA
An NC State researcher has developed a new way to get CRISPR/Cas9 into plant cells without inserting foreign DNA. This allows for precise genetic deletions or replacements, without inserting foreign DNA. Therefore, the end product is not a genetically modified organism, or GMO.
CRISPR/Cas9 is a tool that can be used to precisely cut and remove or replace a specific genetic sequence. The Cas9 protein serves as a pair of molecular scissors, guided to the specific genetic target by an easily swapped RNA guide. Basically, it seeks out a specific genetic sequence and, when it finds that sequence, cuts it out. Once the target DNA is snipped, it can be deleted or replaced.
The CRISPR/Cas9 system has tremendous potential for improving crops by changing their genetic code. That does not necessarily mean inserting foreign DNA, but the systems used to deliver CRISPR/Cas9 into a plant’s cells often do, which means the relevant crop is a GMO. GMOs undergo through a rigorous evaluation process and many consumers prefer non-GMO products.
The U.S. Department of Agriculture (USDA) and the Food and Drug Administration regulate genetically engineered crops, and have standards defining what GMO crops are. These are focused on the presence of DNA sequences from other species being present in the end product.
Deleting or turning down a gene, such as the one responsible for turning sliced apples brown, does not introduce foreign DNA and thus is a non-GMO method. Similarly, altering the expression of a gene related to pest resistance in a variety of sweetpotato to make it more resistant, could be a non-GMO method.
In a new study published in the journal Plant Cell Reports, Wusheng Liu, a plant biologist and biotechnologist in the Department of Horticultural Science, demonstrated a new way of introducing the Cas9 protein and guide RNA into plant cells, which does not involve foreign DNA.
“This was the first time anyone has come up with a method to deliver the Cas9 protein through lipofection into plant cells,” Liu said. “Our major achievement was to make that happen. Also, since many consumers prefer non-GMO specialty crops, this method delivers the Cas9 protein in a non-GMO manner.”
Lipofection is a method that uses positively charged lipids, somewhat like those found in dish soap, to form a bubble-like liposome surrounding the Cas9/gRNA complex. The liposome binds to and then fuses with the plant cellular membrane, introducing its CRISPR cargo into the plant cell. It has been successfully used to deliver the CRISPR/Cas9 protein complex into mammalian cells.

An image showing CRISPR/Cas9 protein — labeled with a green fluorescent protein — inside a plant cell after 6 and 48 hours. Image courtesy Wusheng Liu.
“Many programs worldwide are focusing on CRISPR/Cas9 DNA delivery,” Liu said. “There’s only very limited amount of research focused on Cas9 protein delivery. But protein delivery has a lot of advantages.”
First of all, by delivering the Cas9 protein instead of the DNA sequence of Cas9, there is no transfer of specific DNA sequences from one species to another. The Cas9 protein lasts for three to five days and then is degraded. This reduces cutting at unwanted locations, called off-target cleavage, Liu said.
Also, the most common method of introducing DNA into plants is called Agrobacterium-mediated transformation. Agrobacterium is a group of bacteria that cause plant diseases. Scientists cannot control where the new DNA is added to the plant genome with this method, said Liu. Additionally, this method does not work for many elite varieties of crops which are very difficult to transform. Also, since the process introduces foreign DNA, the end product is a GMO.
On the other hand, the process of introducing CRISPR/Cas9 in a liposome requires that the tough, outer wall of the plant cell be removed. Plant cells without the cell wall are called protoplasts. Converting this protoplast into a shoot, and then a whole plant, requires a careful combination of plant hormones and nutrients. Methods for regenerating plants from protoplasts have been developed for more than 50 types of crops including wheat, tomatoes, strawberries and tobacco, said Liu. However, the methods have not been worked out for every crop.
Liu is also working on a few other methods of introducing the Cas9 protein into plant cells that do not require removing the cell wall.
One of these methods uses nanoparticles to introduce the Cas9 protein into pollen grains. Then, when the pollen is used to fertilize a female flower, the pollen tube will introduce Cas9 into the ovule along with the sperm. Some percentage of the resulting seed will have the desired genetic edits produced by the CRISPR/Cas9 complex. He would like to use this method to introduce Cas9 protein into tomato and hemp first, and eventually adapt them to other sexually reproduced crops, he said.
This research is funded by the USDA Agriculture and Food Research Initiative (AFRI) Agricultural Innovations through Genome Editing program.
Liu’s innovation has not gone unnoticed by his colleagues. Tom Ranney and Craig Yencho, professors within the Department of Horticultural Science, are among those who are collaborating with Liu to apply these non-GMO methods to advance beneficial traits in nursery crops and sweetpotatoes, respectively.
“Developing these systems for other specialty crops, including nursery crops and sweetpotatoes would be game changing,” Ranney said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
CRISPR-Cas9
- CRISPR Combined with Glowing Proteins for Viral Detection
Finally, the technology can provide a result in as little as 20 minutes. Study in journal ACS Central Science: Glow-in-the-Dark Infectious Disease Diagnostics Using CRISPR-Cas9-Based Split Luciferase ...
- Researchers devise new strategies to overcome a key CRISPR flaw
When you try to give Cas9 to a patient to snip its DNA, that person’s immune system may recognize that the protein comes not from us but from our ancient microbial foes. And it might then attack.
- CRISPR-Cas9 – Genetic Scissors at Work
In 2020, the Nobel Prize in Chemistry was awarded to Jennifer A. Doudna and Emmanuel Charpentier for their development and understanding of the gene-editing tool, CRISPR-Cas9. Charpentier has been ...
- Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
Ligand's shares gained 6.9% in the last three months. CRISPR is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. Its lead pipeline candidate is exagamglogene ...
- Here's Why You Should Add CRISPR Stock to Your Portfolio
CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.
Go deeper with Google Headlines on:
CRISPR-Cas9
[google_news title=”” keyword=”CRISPR-Cas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cas9 protein
- Researchers discover how a mutation in the desmosomal gene leads to arrhythmogenic cardiomyopathy
Mutations in genes that form the desmosome are the most common cause of the cardiac disease arrhythmogenic cardiomyopathy (ACM), which affects one in 2000 to 5000 people worldwide.
- Gene-editing Treatment Relieves Debilitating Symptoms
Kiwi patients with a painful and debilitating inherited illness say gene-editing therapy has changed their lives. Kiwi patients with a painful and debilitating inherited illness say gene-editing ...
- From mutation to arrhythmia: Desmosomal protein breakdown as an underlying mechanism of cardiac disease
Mutations in genes that form the desmosome are the most common cause of the cardiac disease arrhythmogenic cardiomyopathy (ACM), which affects one in 2,000 to 5,000 people worldwide. Researchers from ...
- Protein Found to Play a Role in Rare Genetic Immune Disorders
Researchers at the Garvan Institute of Medical Research report they have discovered a protein that plays a critical role in immune cell function is at the root of immunodeficiency disorders. PI3K ...
- Mammalian Transient Protein Expression Market is expected to surpass US$ 1581.6 million by 2033 | FMI Study
As per the latest market research conducted by FMI, the global Mammalian Transient Protein Expression Market is likely to record a CAGR of 8.5% from 2023 to 2033. In 2023, the market size is projected ...
Go deeper with Google Headlines on:
Cas9 protein
[google_news title=”” keyword=”Cas9 protein” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]